Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment
AssigneePolaris Group
InventorsRichard Showalter, Robert Almassy, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
Claims27
A therapeutic composition comprising an isolated, recombinant arginine deiminase (ADI) that is at least 90% pure, or a fragment thereof having ADI activity, and a pharmaceutically-acceptable carrier, wherein the ADI displays at least 95% sequence identity to SEQ ID NO:10 and has reduced cross-reactivity with patient anti-ADI-PEG 20 antibodies, and wherein the composition is sterile and substantially endotoxin-free.
Dependencies are inferred from the claim text.